Geographic and Demographic Representation in Industry-Sponsored, US-Based Clinical Trials of Systemic Lupus Erythematosus Therapies.
Joshua J SkydelReshma RamachandranSakinah C SuttiratanaJoseph R RossChristopher M BurnsJoshua D WallachPublished in: The Journal of rheumatology (2023)
Clinical research into potential therapies for systemic lupus erythematosus (SLE) has increased over the last 2 decades, driven by the discovery of new targetable pathways, yet uncertainty persists over which patients benefit from new therapies. 1 Black patients and other minoritized populations, which disproportionately experience severe disease, are underrepresented in SLE trials. 2 .
Keyphrases
- systemic lupus erythematosus
- end stage renal disease
- disease activity
- clinical trial
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- small molecule
- randomized controlled trial
- patient reported outcomes
- high throughput
- early onset
- patient reported
- single cell
- double blind
- placebo controlled